<DOC>
	<DOCNO>NCT02698111</DOCNO>
	<brief_summary>The investigator clinical trial ( patient metastatic nasopharyngeal carcinoma treat donafenib failure standard therapy ) ass safety efficacy donafenib patient metastatic nasopharyngeal carcinoma , progress approve standard therapy .</brief_summary>
	<brief_title>Donafenib Monotherapy Previously Treated Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>The study open-label , phase 1B study recruit 18 patient . Patients eligible participate histological cytological documentation nasopharyngeal carcinoma . They must receive locally currently approve standard therapy disease progression last administration last standard therapy stop standard therapy unacceptable toxic effect . The available standard therapy include one drug follow license : fluoropyrimidine , taxane , DDP , gemcitabine . Patients age 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; life expectancy least 3 month ; adequate bone-marrow , liver , renal function start trial . Patients could participate previously receive sorafenib uncontrolled medical disorder . All patient receive best supportive care , exclude investigational antitumour agent antineoplastic chemotherapy , hormonal therapy , immunotherapy.Patients receive oral donafenib 200mg ( CM4307 ) 4 week cycle disease progression , death , unacceptable toxic effect , withdrawal consent patient , decision treat physician discontinuation would patient 's best interest.The primary endpoint safety.The second endpoint progression-free survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Have histological cytological documentationof nasopharyngeal carcinoma ; Have receive system standard therapy disease progression ( RECIST1.1 ) stop standard therapy unacceptable toxic effect . Standard therapies include many follow licensed : fluoropyrimidine , taxol , DDP , gemcitabine ; Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Life expectancy least 3 month ; Have adequate bonemarrow , liver , renal function start trial . • Prothrombin time international normalized ratio≤2；or prothrombin time≤16 second ; activate partial thromboplastin time ( APTT ) ≤43 second ; TT≤21 second . Patients prior treatment sorafenib ; Patients Central nervous system ( CNS ) involvement ; patient uncontrolled medical disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>nasopharyngeal carcinoma , donafeinib</keyword>
</DOC>